Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sagimet Biosciences (SGMT) Cash from Financing Activities (2023 - 2024)

Sagimet Biosciences has reported Cash from Financing Activities over the past 2 years, most recently at -$27000.0 for Q2 2024.

  • Quarterly results put Cash from Financing Activities at -$27000.0 for Q2 2024, up 97.03% from a year ago — trailing twelve months through Dec 2024 was $104.8 million (up 21.65% YoY), and the annual figure for FY2025 was $275000.0, down 99.74%.
  • Cash from Financing Activities for Q2 2024 was -$27000.0 at Sagimet Biosciences, down from $104.8 million in the prior quarter.
  • Over the last five years, Cash from Financing Activities for SGMT hit a ceiling of $104.8 million in Q1 2024 and a floor of -$910000.0 in Q2 2023.